NBY:NYE-NovaBay Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.1112

Change

-0.03 (-20.00)%

Market Cap

USD 0.91M

Volume

7.79M

Analyst Target

USD 2.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NVO Novo Nordisk A/S

N/A

USD 562.30B
BHVN Biohaven Pharmaceutical Holdin..

N/A

USD 3.44B
HTD John Hancock Tax Advantaged Di..

N/A

USD 2.41B
DNA Ginkgo Bioworks Holdings

N/A

USD 2.17B
RCUS Arcus Biosciences Inc

N/A

USD 1.49B
NUVB Nuvation Bio Inc

N/A

USD 0.64B
ADCT ADC Therapeutics SA

N/A

USD 0.36B
PGP PIMCO Global StocksPLUS & Inco..

N/A

USD 0.32B
CYBN Cybin Inc

N/A

USD 0.29B
LCTX Lineage Cell Therapeutics Inc

N/A

USD 0.28B

ETFs Containing NBY

VCIP:CA Vanguard Conservative Inc.. 46.83 % 0.25 %

N/A

CAD 0.20B
VBAL:CA Vanguard Balanced Portfol.. 23.26 % 0.25 %

N/A

CAD 2.65B
VGRO:CA Vanguard Growth Portfolio 11.61 % 0.25 %

N/A

CAD 4.84B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -44.40% 21% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -44.40% 21% F 1% F
Trailing 12 Months  
Capital Gain -93.26% 3% F N/A F
Dividend Return N/A N/A N/A N/A N/A
Total Return -93.26% 3% F N/A F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -39.75% 6% D- 1% F
Dividend Return -39.75% 6% D- 1% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 62.17% 44% F 14% F
Risk Adjusted Return -63.94% 28% F 5% F
Market Capitalization 0.91M 3% F 1% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector